Volume 4, Issue 9
Editorialp. 777–779
Communicating trial results to study volunteers: what does the future hold?
Author(s): Zachary P Hallinan, Kenneth A Getz
Editorialp. 781–783
Managing safety in early phase trials: is there a gold standard?
Author(s): Anja Slikkerveer
Commentaryp. 785–789
Exploring the challenges, impacts and implications of risk-based monitoring
Author(s): Richard C Zink
Clinical Trail Outcomesp. 791–823
HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations
Author(s): Edward L Nelson
Clinical Trail Outcomesp. 825–838
The evolving field of post-transplant therapy in multiple myeloma
Author(s): Sarah A Holstein, & Philip L McCarthy
Clinical Trail Outcomesp. 839–846
Newly available treatments for epilepsy: review of clinical studies of lacosamide, ezogabine, perampanel and eslicarbazepine acetate
Author(s): Steve S Chung
Clinical Trail Outcomesp. 847–865
AbobotulinumtoxinA for the treatment of upper limb spasticity
Author(s): Wolfgang H Jost
